Chi Advisors LLC Ultragenyx Pharmaceutical Inc. Transaction History

Chi Advisors LLC

$203 Million
Q3 2023

A detailed history of Chi Advisors LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Chi Advisors LLC holds 215,000 shares of RARE stock, worth $11.7 Million. This represents 3.78% of its overall portfolio holdings.

Number of Shares

215,000

Previous 85,000 152.94%

Holding current value

$11.7 Million

Previous $3.92 Million 95.46%

% of portfolio

3.78%

Previous 1.47%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$34.92 - $46.66 $4.54 Million - $6.07 Million	130,000 Added 152.94%	215,000 $7.66 Million
Q2 2023 Aug 11, 2023	BUY	$37.35 - $52.15 $3.17 Million - $4.43 Million	85,000 New	85,000 $3.92 Million
Q2 2021 Aug 11, 2021	SELL	$92.19 - $115.71 $184,380 - $231,420	-2,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$106.9 - $167.73 $106,900 - $167,730	-1,000 Reduced 33.33%	2,000 $228,000
Q4 2020 Feb 12, 2021	SELL	$84.4 - $177.39 $379,800 - $798,254	-4,500 Reduced 60.0%	3,000 $415,000
Q3 2020 Nov 12, 2020	SELL	$72.98 - $90.0 $401,390 - $495,000	-5,500 Reduced 42.31%	7,500 $616,000
Q2 2020 Aug 12, 2020	SELL	$46.91 - $78.22 $1.24 Million - $2.06 Million	-26,362 Reduced 66.97%	13,000 $1.02 Million
Q1 2020 May 14, 2020	BUY	$33.8 - $62.9 $29,135 - $54,219	862 Added 2.24%	39,362 $1.75 Million
Q4 2019 Feb 14, 2020	BUY	$36.08 - $45.83 $523,160 - $664,535	14,500 Added 60.42%	38,500 $1.64 Million
Q3 2019 Nov 12, 2019	BUY	$42.5 - $63.11 $1.02 Million - $1.51 Million	24,000 New	24,000 $1.03 Million

Others Institutions Holding RARE

# of Institutions

287

Shares Held

88.1M

Call Options Held

505K

Put Options Held

198K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.81B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chi Advisors LLC with notifications on news.

Account